Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 21;10(2):160.
doi: 10.3390/vaccines10020160.

Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant

Ka-Wa Khong  1 , Danlei Liu  1 , Ka-Yi Leung  2 , Lu Lu  2 , Hoi-Yan Lam  2 , Linlei Chen  2 , Pui-Chun Chan  2 , Ho-Ming Lam  1 , Xiaochun Xie  1 , Ruiqi Zhang  1 , Yujing Fan  1 , Kelvin Kai-Wang To  2   3   4 , Honglin Chen  2   3   4 , Kwok-Yung Yuen  2   3   4 , Kwok-Hung Chan  2   3   4 , Ivan Fan-Ngai Hung  1   3   4
Affiliations

Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant

Ka-Wa Khong et al. Vaccines (Basel). .

Abstract

By vaccinating SARS-CoV-2 naïve individuals who have already received two doses of COVID-19 vaccines, we aimed to investigate whether a heterologous prime-boost strategy, using vaccines of different platforms as the booster dose, can enhance the immune response against SARS-CoV-2 virus variants. Participants were assigned into four groups, each receiving different combination of vaccinations: two doses of BNT162b2 followed by one dose of BNT162b2 booster (B-B-B); Combination of BNT162b2 (first dose) and CoronaVac (second dose) followed by one dose of BNT162b2 booster (B-C-B); two doses of CoronaVac followed by one dose of CoronaVac booster (C-C-C); two doses of CoronaVac followed by one dose of BNT162b2 booster (C-C-B). The neutralizing antibody in sera against the virus was determined with live virus microneutralization assay (vMN). The B-B-B group and C-C-B group demonstrated significantly higher immunogenicity against SARS-CoV-2 Wild type (WT), Beta variant (BV) and Delta variant (DV). In addition, the B-B-B group and C-C-B group showed reduced but existing protection against Omicron variant (OV). Moreover, A persistent rise in vMN titre against OV was observed 3 days after booster dose. Regarding safety, a heterologous prime-boost vaccine strategy is well tolerated. In this study, it was demonstrated that using vaccines of different platforms as booster dose can enhance protection against SARS-CoV-2 variants, offering potent neutralizing activity against wild-type virus (WT), Beta variant (BV), Delta variant (DV) and some protection against the Omicron variant (OV). In addition, a booster mRNA vaccine results in a more potent immune response than inactivated vaccine regardless of which platform was used for prime doses.

Keywords: COVID-19; omicron variant; vaccines.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Procedure of the study. vMN: virus microneutralization assay; nAb: neutralizing antibody; WT: SARS-CoV-2 wild type; BV: SARS-CoV-2 Beta variant; DV: SARS-CoV-2 Delta variant; OV: SARS-CoV-2 Omicron variant.
Figure 2
Figure 2
GMT titre of different vaccine combinations against SARS-CoV-2 variants at baseline and post booster vaccination. (a) Wild type; (b) Beta variant; (c) Delta variant; (d) Omicron variant; * = p < 0.05; ns = non-significant.
Figure 3
Figure 3
vMN titre against Omicron variant after booster dose, all groups included; * = p < 0.05; ** = p < 0.005; ns = non-significant.
See this image and copyright information in PMC

References

    1. Walsh E.E., Frenck R.W., Falsey A.R., Kitchin N., Absalon J., Gurtman A., Lockhart S., Neuzil K., Mulligan M.J., Bailey R., et al. Safety and Immunogenicity of Two RNA-Based COVID-19 Vaccine Candidates. N. Engl. J. Med. 2020;383:2439–2450. doi: 10.1056/NEJMoa2027906. - DOI - PMC - PubMed
    1. Zhang Y., Zeng G., Pan H., Li C., Hu Y., Chu K., Han W., Chen Z., Tang R., Yin W., et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect. Dis. 2021;21:181–192. doi: 10.1016/S1473-3099(20)30843-4. - DOI - PMC - PubMed
    1. Folegatti P.M., Ewer K.J., Aley P.K., Angus B., Becker S., Belij-Rammerstorfer S., Bellamy D., Bibi S., Bittaye M., Clutterbuck E.A., et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–478. doi: 10.1016/S0140-6736(20)31604-4. - DOI - PMC - PubMed
    1. Richmond P., Hatchuel L., Dong M., Ma B., Hu B., Smolenov I., Li P., Liang P., Han H.H., Liang J., et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: A phase 1, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397:682–694. doi: 10.1016/S0140-6736(21)00241-5. - DOI - PMC - PubMed
    1. Chen J., Wang R., Gilby N.B., Wei G.W. Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance. arXiv. 2021 doi: 10.1021/acs.jcim.1c01451.2112.01318v1 - DOI - PMC - PubMed

LinkOut - more resources